Xbrane and STADA enter into a co-development agreement for Xlucane
Xbrane Biopharma AB ("Xbrane") and STADA Arzneimittel AG ("STADA") have entered into a co-development agreement for Xlucane, a Lucentis® (ranibizumab) biosimilar.
...
Continue Reading →
